CommercialCoverageMedium impact
08.02.05d, Retifanlimab-dlwr (Zynyz®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 4, 2026
We identified it
Jun 19, 2026
Summary
New medical necessity criteria have been established for Retifanlimab-dlwr (Zynyz®), a specialty pharmacy medication. This policy update defines the coverage requirements and documentation standards for this oncology drug.
Action Required
By May 4, 2026: Billing team must review and implement new medical necessity criteria for Retifanlimab-dlwr (Zynyz®) claims. Update prior authorization processes and ensure providers document medical necessity according to new policy requirements. Verify coverage criteria are met before submitting claims to prevent denials.